{"id":"pandemic-influenza-vaccine-gsk2340272a","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By stimulating the body's immune system to produce antibodies and immune cells that recognize and attack pandemic influenza virus, this vaccine helps to prevent infection and reduce the severity of symptoms.","oneSentence":"This vaccine induces an immune response against pandemic influenza.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:26.066Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of pandemic influenza"}]},"trialDetails":[{"nctId":"NCT00972517","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-29","conditions":"Influenza","enrollment":245},{"nctId":"NCT00971321","phase":"PHASE2","title":"Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":157},{"nctId":"NCT01003418","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-17","conditions":"Influenza","enrollment":8},{"nctId":"NCT01014091","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-12-01","conditions":"Influenza","enrollment":60},{"nctId":"NCT01161160","phase":"PHASE2","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Influenza","enrollment":209},{"nctId":"NCT00971425","phase":"PHASE3","title":"Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":145},{"nctId":"NCT00964158","phase":"PHASE3","title":"Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":210},{"nctId":"NCT00996853","phase":"","title":"Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-31","conditions":"Influenza","enrollment":9206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pandemic influenza vaccine GSK2340272A","genericName":"Pandemic influenza vaccine GSK2340272A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine induces an immune response against pandemic influenza. Used for Prevention of pandemic influenza.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}